Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Autosomal dominant form of osteopetrosis (disease).
No HPO annotations are available for this condition.
To date, approximately 300 individuals have been identified with a pathogenic variant in CLCN7 . The three different associated phenotypes are described in this section.
ARO is a systemic, life-threatening disorder. Onset of symptoms is at birth. Without treatment, life span is approximately ten years (although rare exceptions of far longer survival have occurred). Note: Many of the most complete clinical descriptions of ARO were published prior to the discovery of the causative gene. Possible clinical manifestations of ARO include the following.
The spectrum of CLCN7-related osteopetrosis includes the following: • Autosomal recessive osteopetrosis (ARO; infantile malignant CLCN7-related autosomal recessive osteopetrosis) • Intermediate autosomal osteopetrosis (IAO) • Autosomal dominant osteopetrosis type II (ADOII; Albers-Schnberg disease) Suggestive Findings A CLCN7-related osteopetrosis should be suspected in individuals with osteosclerosis noted on radiographs, which may be accompanied by hypocalcemia and resulting convulsions, anemia, thrombocytopenia, visual impairment, and/or central nervous system involvement. Table 1. Diagnostic Features of the Subtypes of CLCN7-Related Osteopetrosis Finding | Subtype of CLCN7-Related Osteopetrosis
No approved treatments are currently available for autosomal dominant osteopetrosis. An additional 1 compound holds orphan drug designation.
While no drugs are FDA-approved specifically for autosomal dominant osteopetrosis, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for autosomal dominant osteopetrosis. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor |
|---|
Table 9. Recommended Surveillance for Individuals with Infantile Malignant CLCN7-Related Autosomal Recessive Osteopetrosis (ARO)
System/Concern |
|---|
No clinical trials have been registered for autosomal dominant osteopetrosis.
25 publications have been identified in PubMed for autosomal dominant osteopetrosis. Research spans Case Report / Case Series (48%), Review / Meta-Analysis (22%), and Basic Science / Preclinical (9%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 11 | 48% |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 11:55 AM UTC
Skeletal findings
Source: GeneReviews — "CLCN7-Related Osteopetrosis"
ARO | IAO | ADOII |
|---|---|---|
Radiographic changes | Pathognomonic1 | Characteristic2 |
Hypocalcemia | Severe to absent | Absent |
Anemia | Severe to moderate | Mild to absent |
Thrombocytopenia | Severe to absent | Absent |
Visual impairment | Frequent | Rare |
CNS involvement | Severe to absent4 | Absent |
Age of onset of symptoms | Birth | First 2 years |
Inheritance | AR | AR or AD |
Source: GeneReviews — "CLCN7-Related Osteopetrosis"
Pathogenic variants in CLCN7 account for 13% of the infantile autosomal recessive osteopetrosis (ARO), 40% of the recessive intermediate autosomal osteopetrosis (IAO), 60% of the dominant IAO, and 99% of the autosomal dominant osteopetrosis type II (ADOII) [Authors, personal observation]. ARO Table 3. Other Types of Autosomal Recessive Osteopetrosis
Gene | Disorder | Clinical Characteristics | Features Distinguishing this Disorder from CLCN7-Related ARO |
|---|---|---|---|
CA2 | ARO w/renal tubular acidosis (RTA) (OMIM 259730) | Generalized osteosclerosis. Cerebral calcifications are typical may be assoc w/ID.1 | Onset of ARO w/RTA is usually later than in infantile malignant form of ARO disease course is milder. |
OSTM1 | OSTM1-related ARO (OMIM 259720) | ~4% of ARO is caused by pathogenic variants in OSTM1. Extremely severe form of ARO w/CNS involvement2 that is indistinguishable from most severe forms of CLCN7-related ARO. | OSTM1-related ARO is frequently assoc w/structural brain anomalies. |
PLEKHM1 | PLEKHM1-related ARO (OMIM 611497) | Very rare, can look like ADOII | PLEKHM1-related ARO appears to be very mild can regress w/ age.3 One person w/PLEKHM1-related ARO caused by a heterozygous pathogenic variant has been described.4 |
SNX10 | SNX10-related ARO (OMIM 615085) | ~4% of ARO is caused by pathogenic variants in SNX10; in particular, "Vsterbottenian osteopetrosis" is caused by SNX10 pathogenic variants. Loss of vision, anemia, bone fragility are frequently observed, warranting use of HSCT.5 | SNX10-related ARO appears to be slightly less severe than CLCN7-related ARO. TCIRG1 |
TCIRG1-related ARO | 50% of ARO is caused by pathogenic variants in TCIRG1. | Higher frequency of neurodevelopmental delay seizures in CLCN7-related ARO than in TCIRG1-related ARO.6 Noncoding TCIRG1 variants can cause milder phenotype that resembles ADOII. | — |
TNFRSF11A | Osteoclast-poor ARO (OMIM 612301) | Characterized by onset w/in 1st yr of life typical ARO manifestations. Investigation of bone biopsy is prerequisite for reliable diagnosis. | TNFSF11 pathogenic variants cause a slight T-cell defect TNFRSF11A pathogenic variants can lead to hypogammaglobulinemia similar to a common variable immune deficiency.7 It is crucial to rule out TNFSF11- TNFRSF11A-related ARO, as HSCT is not successful in these persons. |
Source: GeneReviews — "CLCN7-Related Osteopetrosis"
Biomarker and diagnostic research for autosomal dominant osteopetrosis has been reported in the published literature.
Designated
Exclusivity End |
|---|
Designation Status |
|---|
double stranded small interfering RNA composed of a CLCN7G215R allele-specific siRNA | double stranded small interfering RNA composed of a CLCN7G215R allele-specific siRNA | SiSaf Ltd. | 2023 | — | Designated |
General guidelines for diagnosis, therapy, and follow up are available for all forms of osteopetrosis; see . Due to the difference in severity, the evaluation, treatment, and surveillance recommendations for infantile malignant CLCN7-related autosomal recessive osteopetrosis (ARO) and CLCN7-related autosomal dominant osteopetrosis type II (ADOII) differ. The CLCN7-related intermediate autosomal osteopetrosis (IAO) phenotype lies between these two forms and has variable manifestations and prognosis. Therefore, management options for CLCN7-related IAO must be evaluated on an individual basis.
To establish the extent of disease and needs in an individual diagnosed with ARO, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended.
Table 5.
Recommended Evaluations Following Initial Diagnosis in Individuals with Infantile Malignant CLCN7-Related Autosomal Recessive Osteopetrosis (ARO)
System/Concern | Evaluation | Comment
| Baseline radiographic skeletal survey |
| Otorhinolaryngologic exam to evaluate for choanal stenosis assoc w/sclerosis of skull base |
Hypocalcemia
secondary hyper-
parathyroidism | Calcium concentrations in blood urine |
Anemia
thrombocytopenia | CBC w/reticulocyte count |
Abdominal ultrasound | Evaluate for hepatosplenomegaly assoc w/extrameduallry hematopoeisis.
Neurologic
Source: GeneReviews — "CLCN7-Related Osteopetrosis"
ADOII
Activities with high fracture risk should be avoided.
Orthopedic surgery should only be performed when absolutely necessary and the surgeon should be aware of potential complications and difficulties in handling osteopetrotic bone.
Source: GeneReviews — "CLCN7-Related Osteopetrosis"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "CLCN7-Related Osteopetrosis"
View trials for autosomal dominant osteopetrosis
Evaluation
Frequency |
|---|
Bone marrow failure | CBC | Annually at a minimum Visual loss |
Dental issues | Dental eval | Every 6-12 mos or as directed |
Potential for graft failure after HSCT | Transplant center surveillance | As directed by specialists CBC = complete blood count; HSCT = hematopoietic stem cell transplantation Table 10. |
Recommended Surveillance for Individuals with CLCN7-Related Autosomal Dominant Osteopetrosis Type II (ADOII) System/Concern | Evaluation | Frequency |
Anemia thrombocytopenia | CBC | At least annually Visual loss |
Dental issues | Dental eval | Every 6-12 mos or as directed |
Source: GeneReviews — "CLCN7-Related Osteopetrosis"
Research summaries
5 |
22% |
Laboratory research | 2 | 9% |
Disease patterns and progression | 2 | 9% |
Other research | 1 | 4% |
Testing and diagnosis research | 1 | 4% |
New treatment approaches | 1 | 4% |
Najdanović JG (2026). [PMID: 42131975](https://pubmed.ncbi.nlm.nih.gov/42131975/). *Hum Gene Ther*. [Review / Meta-Analysis]
Bustos-Merlo A (2026). [PMID: 41505949](https://pubmed.ncbi.nlm.nih.gov/41505949/). *Medicina clinica*. [Case Report / Case Series]
Econs MJ (2026). [PMID: 40913471](https://pubmed.ncbi.nlm.nih.gov/40913471/). *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*. [Epidemiology / Natural History]
Donati S (2026). [PMID: 42096006](https://pubmed.ncbi.nlm.nih.gov/42096006/). *Curr Osteoporos Rep*. [Review / Meta-Analysis]
Polgreen LE (2025). [PMID: 38661205](https://pubmed.ncbi.nlm.nih.gov/38661205/). *The Journal of clinical endocrinology and metabolism*. [Epidemiology / Natural History]
Lopez-Aldazabal V (2025). [PMID: 40833355](https://pubmed.ncbi.nlm.nih.gov/40833355/). *Veterinary medicine and science*. [Case Report / Case Series]
Bae S (2025). [PMID: 41431003](https://pubmed.ncbi.nlm.nih.gov/41431003/). *Medicine*. [Case Report / Case Series]
Zhou R (2025). [PMID: 39930640](https://pubmed.ncbi.nlm.nih.gov/39930640/). *The Journal of clinical endocrinology and metabolism*. [Diagnostic / Biomarker]
Xu J (2025). [PMID: 39934917](https://pubmed.ncbi.nlm.nih.gov/39934917/). *Stem cell research & therapy*. [Gene Therapy / Novel Therapeutics]
Sha Y (2025). [PMID: 40165215](https://pubmed.ncbi.nlm.nih.gov/40165215/). *BMC biology*. [Basic Science / Preclinical]